SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Miyamura Takako)
 

Sökning: WFRF:(Miyamura Takako) > (2024) > Optimized cytogenet...

  • van Weelderen, Romy E.Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands (författare)

Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • American Society of Hematology,2024
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-227831
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-227831URI
  • https://doi.org/10.1182/bloodadvances.2023011771DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • A comprehensive international consensus on the cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Study Group study on 1256 children with KMT2A-r AML aims to validate the prognostic value of established recurring KMT2A fusions and additional cytogenetic aberrations (ACAs) and to define additional, recurring KMT2A fusions and ACAs, evaluating their prognostic relevance. Compared with our previous study, 3 additional, recurring KMT2A-r groups were defined: Xq24/KMT2A::SEPT6, 1p32/KMT2A::EPS15, and 17q12/t(11;17)(q23;q12). Across 13 KMT2A-r groups, 5-year event-free survival probabilities varied significantly (21.8%-76.2%; P < .01). ACAs occurred in 46.8% of 1200 patients with complete karyotypes, correlating with inferior overall survival (56.8% vs 67.9%; P < .01). Multivariable analyses confirmed independent associations of 4q21/KMT2A::AFF1, 6q27/KMT2A::AFDN, 10p12/KMT2A::MLLT10, 10p11.2/KMT2A::ABI1, and 19p13.3/KMT2A::MLLT1 with adverse outcomes, but not those of 1q21/KMT2A::MLLT11 and trisomy 19 with favorable and adverse outcomes, respectively. Newly identified ACAs with independent adverse prognoses were monosomy 10, trisomies 1, 6, 16, and X, add(12p), and del(9q). Among patients with 9p22/KMT2A::MLLT3, the independent association of French-American-British-type M5 with favorable outcomes was confirmed, and those of trisomy 6 and measurable residual disease at end of induction with adverse outcomes were identified. We provide evidence to incorporate 5 adverse-risk KMT2A fusions into the cytogenetic risk-group stratification of KMT2A-r pediatric AML, to revise the favorable-risk classification of 1q21/KMT2A::MLLT11 to intermediate risk, and to refine the risk-stratification of 9p22/KMT2A::MLLT3 AML. Future studies should validate the associations between the newly identified ACAs and outcomes and unravel the underlying biological pathogenesis of KMT2A fusions and ACAs.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Harrison, Christine J.Leukemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom (författare)
  • Klein, KimPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Department of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands (författare)
  • Jiang, YilinPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands (författare)
  • Abrahamsson, JonasDepartment of Pediatrics, Institute of Clinical Sciences, Salgrenska University Hospital, Gothenburg, Sweden (författare)
  • Alonzo, ToddDivision of Biostatistics, University of Southern California, CA, Los Angeles, United States (författare)
  • Aplenc, RichardDivision of Oncology, Children's Hospital of Philadelphia, PA, Philadelphia, United States (författare)
  • Arad-Cohen, NiraDepartment of Pediatric Hematology-Oncology, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel (författare)
  • Bart-Delabesse, EmmanuelleInstitut Universitaire du Cancer Toulouse-Oncopole, Laboratoire d'Hématologie Secteur Génétique des Hémopathies, Toulouse, France (författare)
  • Buldini, BarbaraDivision of Pediatric Hematology, Oncology, and Stem Cell Transplant, Department of Maternal and Child Health, Padua University, Padua, Italy (författare)
  • De Moerloose, BarbaraDepartment of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium (författare)
  • Dworzak, Michael N.Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, St. Anna Children's Cancer Research Institute, Vienna, Austria (författare)
  • Elitzur, SarahDepartment of Pediatric Hematology and Oncology, Schneider Children's Medical Center, Tel Aviv University, Tel Aviv, Israel (författare)
  • Fernández Navarro, José M.Department of Pediatric Oncohematology, Hospital Universitari i Politècnic la Fe, Valencia, Spain (författare)
  • Gamis, AlanDepartment of Hematology and Oncology, Children's Mercy Hospital, MO, Kansas City, United States (författare)
  • Gerbing, Robert B.Department of Statistics, Children's Oncology Group, CA, Monrovia, United States (författare)
  • Goemans, Bianca F.Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands (författare)
  • de Groot-Kruseman, Hester A.Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; DCOG, Dutch Childhood Oncology Group, Utrecht, Netherlands (författare)
  • Guest, ErinDepartment of Hematology and Oncology, Children's Mercy Hospital, MO, Kansas City, United States (författare)
  • Ha, Shau-YinDepartment of Pediatrics & Adolescent Medicine, Hong Kong Children's Hospital, Kowloon Bay, Hong Kong (författare)
  • Hasle, HenrikDepartment of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark (författare)
  • Kelaidi, CharikleiaDepartment of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece (författare)
  • Lapillonne, HélèneDepartment of Pediatric Hematology and Oncology, Hôpital Armand Trousseau, Paris, France (författare)
  • Leverger, GuyDepartment of Pediatric Hematology and Oncology, Hôpital Armand Trousseau, Paris, France (författare)
  • Locatelli, FrancoDepartment of Pediatric Hematology and Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy (författare)
  • Miyamura, TakakoDepartment of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan (författare)
  • Norén-Nyström, UlrikaUmeå universitet,Pediatrik(Swepub:umu)kagr0007 (författare)
  • Polychronopoulou, SophiaDepartment of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece (författare)
  • Rasche, MareikeDepartment of Pediatric Hematology and Oncology, University Hospital Essen, Essen, Germany (författare)
  • Rubnitz, Jeffrey E.Department of Oncology, St. Jude Children's Research Hospital, TN, Memphis, United States (författare)
  • Stary, JanDepartment of Pediatric Hematology and Oncology, University Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic (författare)
  • Tierens, AnneDepartment of Pathobiology and Laboratory Medicine, University Health Network, Toronto General Hospital, ON, Toronto, Canada (författare)
  • Tomizawa, DaisukeChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan (författare)
  • Zwaan, C. MichelPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Erasmus Medical Center Sophia Children's Hospital, Rotterdam, Netherlands (författare)
  • Kaspers, Gertjan J.L.Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands (författare)
  • Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, NetherlandsLeukemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Blood Advances: American Society of Hematology8:12, s. 3200-32132473-95292473-9537

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy